[Skip to Content]
[Skip to Content Landing]
Nov 2011

Amyloid ImagingLiberal or Conservative? Let the Data Decide

Arch Neurol. 2011;68(11):1377-1378. doi:10.1001/archneurol.2011.152

Although disagreement about the role that the β-amyloid (Aβ) protein plays in Alzheimer disease (AD) abounds, it continues to occupy a central position in both theories of etiology and diagnostic schema. Recently revised criteria for the diagnosis of AD and predementia AD-related conditions include the measurement of Aβ in cerebrospinal fluid or the brain to determine the likelihood of AD.13 It is not surprising, therefore, that the use of positron emission tomography (PET) to detect and quantify Aβ is a topic of active investigation. Although the short-lived carbon 11–labeled Pittsburgh Compound B ([11C]PIB) has been available for a number of years and is the most widely studied PET amyloid imaging agent, the recent advent of longer-lived radiopharmaceuticals labeled with fluorine 18 (18F) have made this technology more available and commercially viable. In this issue of the Archives, 2 articles4,5 dealing with 2 different 18F amyloid imaging agents continue to advance the field.

First Page Preview View Large
First page PDF preview
First page PDF preview